Hepatitis C

← Back to Index (🍴 Gastroenterology)

Virology And Transmission

Viral Characteristics

Single-stranded RNA virus.
Classified within Flaviviridae family.
Comprises six major genotypes (1-6) and numerous subtypes.
High RNA polymerase error rate produces multiple viral variants (quasispecies).
Quasispecies generation facilitates evasion of host immune surveillance.

Transmission Dynamics

Vertical (mother-to-infant) transmission represents primary acquisition route in pediatric population.
Vertical transmission risk approximates 5-7% per pregnancy.
Concomitant maternal human immunodeficiency virus (HIV) infection or high maternal viral load (>3,000,000 IU/mL) elevates vertical transmission risk to 20%.
Horizontal transmission routes include intravenous drug use, contaminated blood products (rare post-1992 screening), and high-risk sexual contact.
Breastfeeding does not increase transmission risk; contraindicated only if maternal HIV coinfection exists.

Clinical Manifestations

Acute Infection

Insidious onset; predominantly asymptomatic or mild clinical course.
Fulminant hepatic failure exceptionally rare.
Incubation period ranges 2 to 24 weeks (mean 7-9 weeks).

Chronic Infection And Extrahepatic Signs

Chronic infection defined by detectable viral ribonucleic acid (RNA) persisting >6 months.
20-40% of infected children achieve spontaneous sustained viral clearance within first 5 years of life.
Remaining majority progress to chronic infection.
Cirrhosis, hepatic failure, and hepatocellular carcinoma represent major long-term morbidities developing over 20-30 years.
Extrahepatic manifestations occur; include essential mixed cryoglobulinemia, membranoproliferative glomerulonephritis, cutaneous vasculitis, porphyria cutanea tarda, and lichen planus.

Diagnostic Evaluation

Age-Specific Testing Protocols

Maternal antibodies undergo passive transplacental transfer, persisting up to 18 months postnatally, confounding early serologic screening.

Patient Age	Diagnostic Modality	Interpretation And Rationale
<18 Months	Quantitative HCV RNA polymerase chain reaction (PCR).	Requires positive testing on two separate occasions after 2 months of age to confirm infection. Anti-HCV IgG unreliable due to maternal antibody persistence.
>18 Months	Anti-HCV IgG (enzyme immunoassay).	Initial screening tool. High false-positive rate in low-risk populations. Does not confer immunity.
>18 Months	Quantitative HCV RNA PCR.	Confirmatory test following positive antibody screen. Differentiates active from resolved infection; monitors treatment response.

Management Protocol

Direct-Acting Antiviral (DAA) Therapy

Goal of therapy: Sustained viral response (SVR), defined as undetectable HCV RNA 12 to 24 weeks following treatment cessation.
SVR correlates with improved histology and halted disease progression.
DAAs replaced highly toxic, poorly tolerated interferon/ribavirin regimens.
DAAs safely approved for pediatric patients $\geq$ 3 years of age.
Achieve SVR rates >95% in pediatric cohorts.

DAA Pharmacological Classes

Regimens combine distinct classes targeting specific viral life cycle proteins to prevent drug resistance.

DAA Class	Suffix	Mechanism Of Action
NS3/4A Protease Inhibitors	"-previr" (e.g., Glecaprevir)	Inhibits viral polyprotein processing.
NS5A Inhibitors	"-asvir" (e.g., Velpatasvir)	Blocks viral replication and assembly.
NS5B Polymerase Inhibitors	"-buvir" (e.g., Sofosbuvir)	Inhibits HCV RNA replication.

Preferred Regimens

Recent advancements utilize pangenotypic agents, eliminating necessity for preliminary genotype testing.

Sofosbuvir-Velpatasvir: Administered once daily for 12 weeks.
Glecaprevir-Pibrentasvir: Administered for 8 weeks.

Surveillance And Prognosis

Infected patients require regular screening with abdominal ultrasonography and serum alpha-fetoprotein to monitor for hepatocellular carcinoma.
Mandate vaccination against Hepatitis A and B to prevent severe superimposed hepatic injury.
DAA therapies facilitate viral eradication before irreversible fibrotic or cirrhotic damage occurs, yielding excellent long-term prognosis.

Perinatal HCV

%%{init: {
  "theme": "base",
  "themeVariables": {
    "background": "#ffffff",
    "primaryColor": "#fff3e6",
    "primaryTextColor": "#d97706",
    "primaryBorderColor": "#d97706",
    "lineColor": "#000000",
    "lineWidth": "3px",
    "fontSize": "15px"
  }
}}%%
graph TD
    A[Pregnant woman with HCV infection:
Prenatal and intrapartum care appropriate for obstetric risk factors
No currently known intervention to reduce MTCT]
    --> B[Neonate born to mother with HCV infection
Mode of delivery has no effect on perinatal infection risk]
    
    B --> C[Exclusive breastfeeding
Breastfeeding is not contraindicated except when the mother has
cracked, damaged, or bleeding nipples]
    
    C --> D[Follow up testing:
Should be done at or after 18 months of age for anti-HCV antibodies]
    
    D --> E[Negative:
HCV infection ruled out;
no action required]
    D --> F[Positive:
HCV infection;
HCV-RNA assay after age 3 years to confirm chronic HCV infection]
    
    F --> G[Consultation with a pediatric gastroenterologist,
treatment with direct-acting antiviral DAA regimens
if approved for child's age irrespective of disease severity]